In the extrinsic pathway of blood coagulation, Factor X is activated by a complex of tissue factor, factor VII(a) and Ca2" ions. Using purified human coagulation factors and a sensitive spectrophotometric assay for Factor Xa, we could demonstrate activation of Factor X by Factor VIIa in the absence of tissue-factor apoprotein, phospholipids and Ca2". This finding allowed a kinetic analysis of the contribution of each of the cofactors. Ca2" stimulated the reaction rate 10-fold at an optimum of 6 mr (Vmax of 1.1 x 10-3 min-') mainly by decreasing the Km of Factor X (to 11.4 /IM). In the presence of Ca2", 25 jtM-phospholipid caused a 150-fold decrease of the apparent Km and a 2-fold increase of the apparent Vmax of the reaction; however, both kinetic parameters increased with increasing phospholipid concentration. Tissue-factor apoprotein contributed to the reaction rate mainly by an increase of the Vmax, in both the presence (40500-fold) and absence (4900-fold) of phospholipid. The formation of a ternary complex of Factor VITa with tissue-factor apoprotein and phospholipid was responsible for a 15 million-fold increase in the catalytic efficiency of Factor X activation. The presence of Ca2+ was absolutely required for the stimulatory effects of phospholipid and apoprotein. The data fit a general model in which the Ca2+-dependent conformation allows Factor VITa to bind tissue-factor apoprotein and/or a negatively charged phospholipid surface resulting into a decreased intrinsic Km and an increased Vmax for the activation of fluid-phase Factor X.
INTRODUCTION
Human coagulation Factor X is a vitamin K-dependent glycoprotein involved in the intrinsic and extrinsic pathway of blood coagulation. The plasma molecule has a reported Mr of 59000-72000 and consists of a heavy chain (Mr 39000-55000) and a light chain (Mr 16000-19000) connected by a disulphide bridge [1] [2] [3] [4] . The protein is the zymogen of the serine-proteinase Factor Xa, which catalyses, in a complex with Factor Va, phospholipid (PL) and Ca2", the conversion of prothrombin into thrombin [1, [5] [6] [7] .
During activation of the zymogen, a small peptide is cleaved from the N-terminal part of the heavy chain [1, 3] . In the intrinsic pathway the activation is catalysed by a complex of Factor IXa, Factor Vllla and Ca2l on a PL surface [8] [9] [10] . In the extrinsic pathway, Factor X is activated by a complex of factor VII(a), tissue factor (TFAP associated with PL membranes) and Ca2" [11] [12] [13] [14] [15] [16] [17] [18] .
Interestingly, the latter complex also contributes indirectly to the activation of Factor X by catalysing the conversion of Factor IX into Factor IXa 118-24].
In general, these key reactions in blood coagulation show a great deal of similarity. Both the enzymes and substrates belong to the class of vitamin K-dependent proteins [6, 25] . Furthermore, the enzymes require Ca2", PL and a protein cofactor for optimal catalytic activity:
Factor Va for Factor Xa, Factor VIIIa for Factor IXa and TFAP for Factor VII(a). However, unlike Factors Va and Vllla, TFAP is an integral membrane protein which does not need to be activated in order to function as a cofactor [14] [15] [16] [17] [18] . Also Factor VII is unique among the coagulation factors in having some intrinsic activity; however, upon activation, the activities of human and bovine Factor VII towards their physiological substrates increase about 25-fold [26, 27] and 120-fold [28] respectively.
In the past years, detailed kinetic analyses have been reported for the activation of Factor X by Factor IXa and the activation of prothrombin by Factor Xa in both the absence and presence of the non-enzymic cofactors [5] [6] [7] [8] [9] [10] [29] [30] [31] [32] [33] . These studies have contributed much to our insight into the role of the individual components involved in these activation reactions, though several mechanisms have been proposed to explain the contributions of the cofactors under the various conditions, differing in whether the PL-bound or soluble form of substrate and enzyme control the reaction rate. Such detailed analyses have not been reported yet for the activation of Factors IX and X by Factor Vlla. Although several investigators have reported kinetic parameters for the extrinsic activation of Factor X and/or Factor IX in plasma or in a purified system [13, [20] [21] [22] [23] [24] [34] [35] [36] , the use of crude tissue-factor extracts hampered the analysis Abbreviations used: PS, L-a-phosphatidyl-L-serine; PC, L-a-phosphatidylcholine; PL, phospholipid; TF(AP), tissue-factor (apoprotein); OVA, ovalbumin; S2337, N-benzoyl-L-isoleUCYI-L-glutamyl(piperidyl)glyCyl-L-arginine p-nitroanilide hydrochloride; S2303, H-D-prolyl-L-phenylalanyl-Larginine p-nitroanilide dihydrochloride; TEA, triethanolamine; TEA/NaCl/OVA, 0.05 M-TEA/0. 1 M-NaCI/5 ,gM-OVA, pH 7.45 (37°C).
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of the individual effects of TFAP and PL in these reactions. Moreover, the radiometric assays used to measure Factor X and/or Factor IX activation [22, 37] were in general not sensitive enough to measure factor VII(a) activity in the absence of tissue factor. In the present study we demonstrate activation of human Factor X by Factor VIIa in the absence of any of the accessory cofactors by using a very sensitive chromogenic assay for Factor Xa. The availability of highly purified human TFAP [18] then allows the systematic kinetic analysis of the contribution of each of the cofactors (Ca2", PL and TFAP) to the activation of Factor X by Factor VIIa. The study was also designed in such a way that previous findings from our laboratory on the intrinsic activation of Factor X [10, 31, 38] could be used.
Preliminary results of this investigation were presented at the Tenth International Congress on Haemostasis and Thrombosis, held in San Diego, CA, U.S.A., on 12 July 1985 [39] .
EXPERIMENTAL Materials
DEAE-Sephadex A-50, Sephadex G-75 and G-200, heparin-Sepharose CL-6B, Protein A-Sepharose and CNBr-activated Sepharose 4B are products of Pharmacia Biotechnology, Uppsala, Sweden. Ultrogel AcA 44 was purchased from LKB, Bromma, Sweden. HeparinSepharose used for the purification of Factor VII(a) was prepared by coupling standard heparin (Organon, Oss, The Netherlands) to CNBr-activated Sepharose 4B (20 mg/g of activated Sepharose), the instructions of the manufacturers being followed. Bio-Beads SM-2, SDS, Triton X-100, acrylamide, NN'-methylenebisacrylamide, NNN'N'-tetramethylethylenediamine, dithiothreitol and Hepes were obtained from Bio-Rad Laboratories, Richmond, CA, U.S.A. Trasylol (aprotinin) and benzamidine hydrochloride were purchased from Bayer, Leverkusen, Germany, and Aldrich Europe, Beerse, Belgium, respectively. OVA (five-times-recrystallized) was obtained from Koch-Light Laboratories, Colnbrook, Slough, Berks., U.K. Bovine serum albumin (grade V), bovine brain L-a-phosphatidyl-L-serine (PS; type P-6641) and egg lecithin L-a-phosphatidylcholine (PC; type P-4139) were obtained from Sigma Chemical Co., St [38] . PL concentrations were determined by phosphate analysis after HC104 combustion [40] .
Purified coagulation factors. Protein concentrations were determined as described by Bradford [41] , with bovine serum albumin as a standard, and from A280/A320 measurements [42] , an A"1 value of 11.6 for Factor X being used [2] . When amounts of coagulation factors are expressed in units, 1 unit refers to the amount of antigen or activity present in 1 ml of pooled normal citrated plasma.
Human Factor VII was purified from citrated plasma to a specific activity of 1750 units of antigen/mg as previously described [43] . The one-chain molecule was quantitatively converted into two-chain Factor VIIa by incubation with purified human Hageman factor fragment fl-XIIa [44] (Mr 30 000 and 33 000 for the unreduced and reduced form respectively) and separated from the activator as previously described [43] . Final preparations of Factor VIla showed one single band of Mr 53000 before reduction and two bands of Mr 34000 (heavy chain) and Mr 28000 (light chain) after reduction on SDS/polyacrylamide gels; these preparations contained less than 0.01 mol of ,J-XIIa/mol of VIIa and were stable for more than 1 year when stored at -20°C in TEA/ NaCl containing 50 % (v/v) glycerol.
Factor X was isolated as a by-product of Factor VII purification, essentially as described previously [38] , except that CaC12 was replaced by BaCl2 during heparinSepharose chromatography; it was dialysed against TEA/NaCl and stored in aliquots at -20 'C. The specific activity of purified Factor X was 190 units/mg as measured by electroimmunoassay as well as spectrophotometrically [3] . Purified Factor X showed one single band of Mr 72000 on non-reducing gels and two bands of Mr 56000 (heavy chain) and 20000 (light chain) on reducing gels. Preparations contained (1.8-2.2) x 10-5 mol of Xa/mol of X.
TFAP was purified from human brain as previously described [18] and stored in aliquots containing 0.02 M-Hepes/0. 15 M-NaCl/0.002 M-EDTA/Triton X-100 (0.25 ml/l), pH 7.45 at -20 'C. The preparations showed one discrete band of Mr 47000 or 49000 on SDS/polyacrylamide gels before and after reduction respectively.
Antibodies against Factor VlI(a). These were isolated from specific rabbit antisera against human Factor VII by affinity chromatography on Factor VII-Sepharose [43] , dialysed against TEA/NaCl and used within 48 h.
Analytical methods
Determination of the initial rate of Factor Xa formation. The rate of activation of Factor X by Factor VIla in the absence or presence of Ca2 , PS/PC and/or TFAP was studied in TEA/NaCl/OVA at 37 'C. The reaction mixtures were assembled in silicone-treated glass tubes according to the following scheme: (1) PS/PC vesicles were preincubated with 0.0167 M-CaCl2 in TEA/NaCl/ OVA in 60 % of the final volume for 15 min to form a stable PL surface (cf. [38] ); (2) TFAP was added, and recombination with the PS/PC was allowed to proceed for 20 min; (3) buffer and Factor VIIa were added and Factor VIla was allowed to bind to recombined TF for 10 min; and (4) the reaction was started by addition of Factor X. When not added, PS/PC, Ca2+ and protein components were replaced by TEA/NaCl, EDTA (0.001 M) and TEA/NaCl/OVA respectively. Stock solutions of Factor VIla and Factor X were pre-diluted in TEA/NaCl/OVA before addition to the reaction mixture. Stock solutions of TFAP were pre-diluted in TEA/NaCl/OVA containing 0.25 ml of Triton X-100/1; because solubilized TFAP was found to be relatively instable when the Triton X-100 concentration fell below its critical micelle concentration of about 0.1 ml/l [45] , a further 5-fold dilution in the same buffer without Triton X-100 was made just before addition to the reaction mixture. Under these conditions more than 900 of the TFAP activity could be recovered in the reaction mixture (when compared with the direct addition of TFAP from the stock solution), while simultaneously the Triton X-100 concentration was reduced to 0.005 ml/l. The latter concentration did not interfere with the stable PS/PC surfaces when final concentrations of 10-100 /tM-PS/PC were used.
The final incubation volumes varied between 0.25 and 1.1 ml. After different time intervals, samples (0.05-0.25 ml) were drawn off and assayed for the amount of Factor Xa formed, the sample taken at zero time being used as the blank (see below). From the proportional increase of the Factor Xa concentration with time, the initial rate of Factor Xa formation (v*) was calculated (nM-Xa/min). The maximum rate of Factor Xa formation at saturating concentrations of Factor X, Vmax, is expressed as mean catalytic-centre activity (mol of Xa/min per mol of VITa). During the measuring period, less than 20 of the Factor X was converted into Factor Xa. For the construction of Lineweaver-Burk and Woolf plots, mean values of v* were calculated from the data of at least three independent experiments, of which the inter-assay coefficients of variation varied between 0.5 and 28.3 00. The Km and Vmax were determined by weighted linear-regression analysis of s/v* versus s (s being the substrate concentration) and lines were drawn accordingly.
acrylamide/litre, except for the analysis of TFAP, where 75 g of polyacrylamide/litre was used. RESULTS Activation of Factor X by Factor Vlla in the absence and presence of Ca2" ions Using a sensitive and specific spectrophotometric assay of Factor Xa we observed activation of Factor X by Factor Vlla in the absence of any cofactor, as shown in Fig. 1 . At 1.0 /tM-Factor X and 6.9 nM-Factor Vlla, the initial rate of Factor Xa formation, v*, was 5.7 x 10-5 nmXa/min. Ca2" enhanced the reaction rate 10-fold at the optimum concentration of 6 mm and gave inhibition at higher concentrations ( Fig. 1) . In both the absence and presence of Ca2", v* was constant with time and proportional to the concentration of Factor Vlla, as illustrated in Figs. 2(a) and 2(b). That indeed Factor VIla was responsible for the observed Factor Xa formation was confirmed by the observation that both reactions could be inhibited by immunopurified antibodies against factor VII(a): 9400 inhibition in the presence of Ca2", 870% inhibition in the absence of Ca2". These findings allowed the further kinetic analysis of the activation of Factor X by Factor Vlla in solution. to 0.9 ml with TEA/NaCl and the chromogenic assay started by addition of 0.1 ml of prewarmed 0.002 M-S2337. Depending on the rate of colour development, the reaction was stopped between 30 and 120 min afterwards by addition of 0.05 ml of 0.5 M-benzamidine/HCl, pH 8, and the A405 measured against the reaction blank (spectrophotometer type PM6; Zeiss, Oberkochen, Germany). The assay was calibrated with known amounts of activesite-titrated Factor Xa and the increase of A405/min per nM-Xa was found to be 0.025. The lower limit of detection of this assay was 1 fmol of Xa.
Other methods. Molar concentrations of Factor X and Factor Xa were determined by use of reference preparations that were active-site-titrated with p-nitrophenyl p-guanidinobenzoate as described previously [31, 38] . [18, 43] . Human ,3-XIIa activity was measured by a chromogenic assay using S2302 as described by Tankersley et al. [44] . SDS/ polyacrylamide-gel electrophoresis under the conditions described by Weber & Osborn [46] was performed as described in [3, 18] ; the gels contained 100 g of poly- formation as illustrated in Fig. 3(a) . Also, v* was found to be proportional to the concentration of Factor VIla (Fig. 3b) . Xa formation by four orders of magnitude. The stimulation was found to be completely dependent on the presence of Ca2". Under our experimental conditions (see the Experimental section), recombination of TFAP with the stable Ca2+-PS/PC surface was a relatively fast process, i.e. at 25 ,tM-PS/PC and 0.2 nM-TFAP the v* was found to be half-maximal after a recombination period of 2 min. Also, the formation of TF-factor VITa complexes was rapidly completed, i.e. within 1-10 min after the addition of Factor VITa, depending on the concentration of Factor VIIa (0.005-0.6 nM). The catalytic complexes formed were stable for at least 20 min. After addition of Factor X, the formation of Factor Xa was found to be linear with time without a measurable lag phase (result not shown); v* was calculated from the linear time courses. To characterize the extrinsic Factor X activator in detail, v* was determined at a fixed concentration of Ca2" (10 mM) and various amounts of TFAP, Factor VITa PS/PC and Factor X. The results are shown in Fig. 4 . The titration curves with TFAP (Fig. 4a, showing five of the ten curves) show that Factor VITa can be saturated with TFAP and that, with increasing concentrations of Factor VITa (2.5-600 pM), more TFAP is needed to saturate the activator. The titration curves with Factor VITa (Fig. 4b, showing an apparent catalytic-centre activity of 24.5 mol of Xa/min per mol of VIIa was calculated; and (3) from the combined data we have calculated that the apparent stoichiometry of TFAP/Factor VITa for the formation of the catalytic complex was 6.1: 1 (mol/mol). Fig. 4(c) shows that the PL concentration can also be rate-limiting in the extrinsic activation of Factor X, a finding which is in agreement with the formation of a Factor VIIa-TFAP-PS/PC ternary complex in the presence of Ca2". At 0.4 nM-TFAP and 0.05 nM-Factor VITa, v* was proportional to the concentration of PS/PC up to 1.0 4UM (see the top curve). With increasing concentrations of PS/PC, a plateau was reached, followed by a decrease in v* at the higher PS/PC concentrations. A similar curve was obtained when the concentrations of Factor VITa and Factor X were varied ( Fig. 4c; lower curve) ; however, at the higher Factor X concentration, less inhibition of v* was observed at increasing concentrations of PS/PC (25-150 /tM). An interesting observation was that, without added PS/PC vesicles, v* was only 100-fold less than at the optimum concentration of PL; this finding is analysed in more detail below.
To determine the kinetic parameters for the activation of Factor X by the Factor VIIa-TFAP-PS/PC complex, v* was measured at different Factor X concentrations under conditions where the enzyme was saturated with TFAP and PS/PC. The data are presented in a doublereciprocal form in Fig. 4(d) . The apparent Km and V.ax were calculated to be 0.055 /aM-Factor X and 81 mol of Xa/min per mol of VITa respectively. We did not observe substrate inhibition, even at 2 /tM-Factor X. From a comparison of these data with those observed in the absence of TFAP (see Fig. 3 c and the above subsection) we conclude that the stimulatory effect of TFAP in the presence of PS/PC and Ca2l is almost completely due to the 40500-fold increase in the apparent catalytic-centre activity of Factor VITa. Activation of Factor X by Factor VIIa in the presence of Ca2" and TFAP TFAP was found to enhance the rate of activation of Factor X by Factor VITa even in the absence of PS/PC vesicles (see the subsection above). This reaction was studied at fixed concentrations of Ca2" (10 mM) and Triton X-100 (0.005 ml/l). Under these conditions a linear time course of Factor Xa formation for at least 30 min was obtained at different concentrations of Factor X (see Fig. 5a ). However, with some of the TFAP preparations we observed that the rates of Factor Xa formation increased with time during the first 10-20 min, particularly at low concentrations of Factor X. As no obvious explanation was available for this phenomenon, such preparations were not used for initial-rate measurements. At 1.0 /tM-Factor X and 0.025 nM-Factor VITa, the addition of 0.4 nM-TFAP enhanced v* more than 30000-fold (compare Figs. 2a and 5a ). This stimulatory effect of TFAP was completely dependent on the presence of Ca2". When Factor VITa (0.025 nM) was titrated with TFAP, saturation was observed at 0.4 nM-TFAP (result not shown), nearly the same concentration as in the presence of PS/PC (cf. Fig. 4c ). These results suggest the formation of a stoichiometric Factor VIla-TFAP-Ca2" complex in the absence of PL, which is in accordance with previously published data [16] [17] [18] . The doublereciprocal plot of v* against Factor X concentration is shown in Fig. 5(b) , and the apparent Km and Vmax. of the catalytic complex were calculated to be 1.7 /tM-Factor X and 5.4 mol of Xa/min per mol of VITa respectively. The kinetic parameters indicate that the stimulatory effect of the apoprotein on the activation of Factor X by Factor VIIa in the presence of Ca2" is exerted by a large increase in the catalytic-centre activity of Factor VITa (4900-fold) and a relatively small decrease in the apparent Km of Factor X (6-fold).
DISCUSSION
In the present study we analysed the activation of Factor X by Factor VITa in the absence or presence of the individual cofactors Ca2", PL and TFAP in a system of highly purified human coagulation factors. The study was made possible by the availability of a sensitive and specific chromogenic end-point assay for Factor Xa. The detection limit of 1 fmol of Xa makes the assay slightly more sensitive than a kinetic variant (detection limit of 2.3 fmol of Xa) previously reported from our laboratory [38] and one or two orders of magnitude more sensitive than the commonly used radiometric assays [22, 37] . Activation of Factor X occurs by cleavage of the Arg52-11e53 peptide bond in the heavy chain of the Vol. 265 zymogen [1] [2] [3] [4] . In the presence of Ca2" and PL, the Factor Xa formed (Factor Xaa) catalyses (a) the cleavage of an Mr-4000 peptide from the C-terminal region of the heavy chain of Factor Xaa., resulting in the formation of Factor Xafl, without any effect on the catalytic properties of the enzyme, and (b) the cleavage of an Mr-13000 peptide from the C-terminal region of the heavy chain of Factor X, resulting in the loss of the active-site serine residue from the Factor X molecule [3] . However, under the conditions (time scale, fraction and concentration of the Factor Xa formed) used in the present study, feedback inactivation of Factor X is negligible (cf. [3] ).
In the present study we demonstrate activation of Factor X by Factor Vlla alone and stimulation of the reaction by Ca2", PS/PC and TFAP. This implies that tissue factor is not an obligatory cofactor for Factor VIla-dependent activation of factor X per se, as has been suggested by other investigators [15, 35] . The activity towards one of its physiological substrates confirms the enzymic nature of Factor VIIa, which is further indicated by its reactivity towards small chromogenic substrates [47] , di-isopropyl fluorophosphate [26, 48] and the serineproteinase inhibitor antithrombin III [26] .
Our findings lead to the following model for the activation of Factor X by Factor VITa: Factor Vlla is enzymically active towards Factor X and this reaction is stimulated by the cofactors Ca2", PL and TFAP. Such a model also applies to Factor IXa in the intrinsic activation of Factor X (cofactors Ca2", PL and Factor VIlla) [8] [9] [10] 31] , Factor Xa in the activation of prothrombin (cofactors Ca2", PL and factor Va) [1, 7, 29, 32] , thrombin in the activation of protein C (cofactors Ca2", PL and thrombomodulin) [49, 50] and activated protein C in the inactivation of Factor Vllla and Factor Va (cofactors Ca2", PL and protein S) [51] . Such an analogy in the mode of action of these serine proteinases is supported by the high degree of sequence similarity between the vitamin K-dependent coagulation factors as deduced from cDNA sequence studies [52] . Table 1 summarizes the effects of the various cofactors on the kinetic parameters of the activation of Factor X by Factor Vlla. In the subsections below we briefly discuss these effects. At the same time we try to accommodate the data in a mechanistic model for extrinsic Factor X activation.
Effects of Ca2l
In the absence of PL and TFAP the stimulatory effect of Ca2l on the reaction rate (10-fold at optimum Ca2l concentration) seems to be due mainly to a decrease in the Km of Factor X (see Figs. 1 and 2 ). In comparison, the activation of Factor X by Factor IXa is stimulated 7-fold at optimal Ca2l concentrations, both in the human [3 1} and in the bovine [9] -system.
The most important feature of Ca2", however, is that it is absolutely required for the functional activity of the other two cofactors (TFAP and PS/PC). Several of these proteins with PL membranes and for binding of Factor VII(a) to TFAP [6, 18, 25, 43, 53, 54] .
Effects of PS/PC
The addition of PS/PC (25 /tM) stimulates the activation of Factor X by Factor VIIa, in both the absence and presence of TFAP (see Figs. 3c and 4c ). In the absence of TFAP the stimulation is mainly due to a 148-fold decrease in the apparent Km of Factor X, although there is also a significant increase in the apparent Vmax of the reaction. Interestingly, with increasing PS/PC concentrations, both the apparent Vmax and the apparent Km of Factor X increase. Very similar observations have been reported for the effects of PS/PC on the activation of Factor X by Factor IXa [9,3 1] and of prothrombin by Factor Xa [29, 33] . In general, this phenomenon has been explained by a model in which enzyme and substrate are concentrated on the PL surface [9, 29] , thus favouring the formation ofenzyme-substrate complexes. However, this model does not always fit the experimental data [31, 33] .
In an attempt to clarify the mechanism underlying the stimulatory effect of PS/PC on the activation of Factor X by Factor VIIa, we estimated the concentrations of free and bound Factor VITa and Factor X under the experimental conditions of the rate determinations (see Fig. 3c ) using a value of 0.002 mol of Factor X/VIIabinding sites per mol of PS/PC [38] [17] in the presence of a considerably higher Triton X-100 concentration (1.0 ml/l). The observed saturation of Factor VIIa with TFAP supports previous findings [16] [17] [18] and suggests that the formation of a stoichiometric complex of Factor VIIa and TFAP in the absence of PL is responsible for a 32900-fold increase in the catalytic efficiency of the activation of Factor X by Factor VIIa.
In the presence of PS/PC, the addition of TFAP results in a 56700-fold increase in the catalytic efficiency of Factor X conversion. This is rather close to the 31 500-fold increase observed in a bovine system when TF replaced PL [13] . The stimulatory effect of human TFAP in the presence of PS/PC is almost exclusively due to the 40 500-fold increase in the apparent Vmax of the reaction.
This increase correlates well with the 1000-100000-fold increase in the affinity of Factor VITa for binding to TFAP-containing PL membranes when compared with 'plain' PL membranes [24, 35, 56] . This suggests that formation of a Factor VIIa-TFAP-PS/PC ternary complex is responsible for the increase in the Factor X activation rate. In agreement with such an hypothesis is that the catalytic complex can be saturated with each of the individual components (Fig. 4) . The apparent stoichiometry of TFAP and Factor VITa for the formation of this complex is 6.1 mol/mol. As each accessible TFAP molecule can bind one molecule of Factor VII [55] , we have to assume that, under our experimental conditions, only a minor fraction of the added TFAP was bound to the PS/PC membranes and/or was accessible for Factor VIIa, which might be due to aggregation of TFAP. Whether such aggregation will affect the catalytic-centre activity of the Factor VIIa-TFAP-PS/PC complex is not known.
Several kinetic studies on the extrinsic activation of Factor X (and Factor IX) by Factor VIIa-TF have been reported in the literature [13, 20, 24, [34] [35] [36] . However, most of these studies have been performed with a crude PLrich TF extract which served as source of both TFAP and PL. For the human system, Warn-Cramer & Bajaj Xa/min per mol of VIIa [35, 36] . The same authors [36] provided evidence that the activity of the TF-Factor VITa complex is regulated by fluid-phase Factor X (intrinsic Km of 0.063 jM-free Factor X). The observed inhibition of the reaction rate at high concentrations of PS/PC (Fig. 4c) or mixed brain PL [57] supports a similar model for the human system. By using the data of Fig. 4(d) VITa for binding to PL surfaces, TFAP may be considered primarily as an evolutionary design for a hydrophobic structure with a high affinity for Factor VIIa.
